Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
PerkinElmer Inc. (PKI) drives innovation in diagnostics, life sciences, and applied markets through advanced scientific solutions. This page aggregates official announcements and verified news about the company's strategic initiatives, financial performance, and technological advancements.
Investors and industry professionals will find timely updates on earnings reports, product launches, and regulatory milestones. Our curated collection simplifies tracking PKI's progress in enabling critical research and improving healthcare outcomes globally.
Key content includes updates on analytical instrumentation developments, partnership announcements with research institutions, and expansions in diagnostic testing capabilities. All materials adhere to strict factual reporting standards without speculative commentary.
Bookmark this page for streamlined access to PerkinElmer's latest corporate communications. Check back regularly for insights into how PKI continues to address complex challenges in scientific discovery and clinical diagnostics.
New Mountain Capital has announced a definitive agreement to acquire PerkinElmer's Applied, Food, and Enterprise Services businesses for up to $2.45 billion. This acquisition includes OneSource laboratory services and various scientific instruments serving multiple markets, including biopharma and food safety. The deal is expected to close in Q1 2023, pending regulatory approvals. Both companies believe this partnership will enhance strategic growth and innovation in their sectors.
PerkinElmer (NYSE: PKI) reported Q2 2022 revenue of $1.23 billion, unchanged from last year, with GAAP EPS from continuing operations at $1.42, down from $2.19 a year ago. The company initiated Q3 guidance of approximately $1.02-1.03 billion in revenue and adjusted EPS of $1.40-1.45, while raising full-year guidance to $4.60-4.64 billion and adjusted EPS of $7.80-7.90. PerkinElmer also announced an agreement to divest its Applied, Food, and Enterprise Services businesses for $2.45 billion, expected to close in Q1 2023.
PerkinElmer has signed an agreement to divest its Applied, Food, and Enterprise Services businesses to New Mountain Capital for $2.45 billion. Of this, $2.30 billion will be received at closing, with $150 million contingent on future valuations. Post-transaction, PerkinElmer will focus solely on Life Sciences and Diagnostics, projected to generate $3.3 billion in 2022 revenue, with over 10% annual organic growth. The divestiture is expected to close in Q1 2023.
The Board of Directors of PerkinElmer, Inc. (NYSE: PKI) has declared a regular quarterly dividend of
PerkinElmer, Inc. (NYSE:PKI) has appointed Dr. Michelle McMurry-Heath to its board of directors, effective July 22, 2022. Dr. McMurry-Heath brings extensive experience in research and science policy, having served as President and CEO of the Biotechnology Innovation Organization. Her strong advocacy for equitable access to medical innovations and leadership roles at Johnson & Johnson and the FDA position her well to contribute to PerkinElmer's growth strategy post-portfolio transformation. The company reported revenues of approximately $5 billion in 2021 and continues to prioritize innovation in healthcare.
PerkinElmer, Inc. (NYSE: PKI) will release its Q2 2022 financial results on August 4, 2022, at 6:00 a.m. ET. A conference call will follow at 8:00 a.m. ET, hosted by CEO Prahlad Singh and CFO Jamey Mock. The call will be accessible via a registration form on their website. A replay will be available from 10:00 a.m. ET the same day. The company reported $5 billion in revenue for 2021 and serves customers in 190 countries.
PerkinElmer (NYSE: PKI) launched the GC 2400™ Platform, an innovative automated gas chromatography solution aimed at enhancing lab productivity and precision. Designed for pharmaceutical, food, environmental, and industrial applications, it combines systems, software, and consumables to streamline operations. Key features include automated sampling, reduced hands-on time, and a wireless touchscreen interface. Built-in sensors promote sustainability by minimizing gas consumption. The platform will be showcased at Analytica Germany and Analytica Latin America.
PerkinElmer (NYSE: PKI) has launched the BioQule™ NGS System, an innovative benchtop solution for next-generation sequencing (NGS) library preparation. This system allows labs to automate the process for up to eight samples, featuring integrated quality control and liquid handling technology. Unlike existing solutions, the BioQule provides in-built quantification of created libraries and requires only 10 ng of starting material. It is suitable for various lab sizes and does not necessitate prior automation experience. The system will be showcased at the AGBT General Meeting in Orlando from June 6-9, 2022.
PerkinElmer reports Q1 2022 revenue of $1.26 billion, down from $1.31 billion a year prior. GAAP EPS from continuing operations is $1.40 compared to $3.37 in Q1 2021. The company initiates guidance for Q2 2022, forecasting revenue of $1.20-1.22 billion and expects adjusted EPS between $2.00-2.05. For the full year, expected revenue is $4.56-4.63 billion with adjusted EPS of $7.15-7.45. Despite revenue declines, the company highlights significant growth in the Discovery & Analytical Solutions segment with a 33% increase.
PerkinElmer, Inc. (NYSE: PKI) has declared a quarterly dividend of $0.07 per share, to be paid on August 12, 2022. This dividend is for shareholders on record as of July 22, 2022. In 2021, the company reported approximately $5 billion in revenue and employs over 16,000 individuals, serving customers across 190 countries. PerkinElmer is part of the S&P 500 Index, indicating its significant presence in the market.
FAQ
What is the market cap of PERKINELMER (PKI)?
